Skip to content

Evaluation of therapeutic effects of Remote ischemic preconditioning and Remote ischemic postconditioning on the lower limb of the patients under coronary artery bypass surgery

Evaluation of therapeutic effects of Remote ischemic preconditioning and Remote ischemic postconditioning on the lower limb of the patients under coronary artery bypass surgery: Multicenter study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220407054445N1
Enrollment
166
Registered
2022-04-29
Start date
2022-04-17
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease. Ischaemic heart diseases

Interventions

Intervention 1: The intervention group: Patients are selected based on the inclusion and exclusion criteria and undergo ischemia induced by a sphygmomanometer cuff (RIPC + RIPostC) an hour prior to an

Sponsors

Rasht University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age range 18 years and above Patients who have undergone on-pump heart surgery and Blood cardioplegia has been used to prevent myocardial injury during ischemia. Patients with EF levels above 30% Patients in whom 3 to 4 coronary arteries are grafted. All patients are operated only by one cardiac surgeon. Both men and women can participate Be able to fill out the consent form.

Exclusion criteria

Exclusion criteria: Age under 18 years History of malignancy during the last 5 years permanent Flutter and atrial fibrillation Patients undergoing off-pump heart surgery Cardiogenic shock Cardiac arrest Significant peripheral artery disease Patients with a systolic blood pressure greater than 160 mm Hg Liver failure (bilirubin above 20 µmol / L or 1.2 mg / dL and INR above 2.0) Pulmonary disease (FEV1 <40%) Renal insufficiency (GFR less than 30ml per minute per 1.73 m2) Concomitant treatment with glibenclamide and nicorandil Unable to fill out consent form Pregnancy

Design outcomes

Primary

MeasureTime frame
Determination of blood level of CK-MB enzyme. Timepoint: On admission, 12 , 24 , 48 and 72 hours after surgery. Method of measurement: patient tests.;2- Determination of blood level of cardiac troponin enzyme. Timepoint: On admission, 12, 24 , 48 and 72 hours after surgery. Method of measurement: patient tests.;Cardiac function. Timepoint: 7 and 40 days after surgery. Method of measurement: Based on echocardiographic results.;Incidence of cardiac dysrhythmias. Timepoint: 72 hours after surgery. Method of measurement: Electrocardiogram.;Determination of the frequency of acute renal injury (AKI). Timepoint: 24, 48 and 72 hours after surgery. Method of measurement: Based on RIFLE criteria and patient test results.;Determination the amount of base deficit in arterial blood. Timepoint: On admission,1 and 2 days after the operation. Method of measurement: patient tests.;Lactate. Timepoint: On admission, 1 and 2 days after the operation. Method of measurement: patient tests.;Liver Enzymes. Timepoint: On admission, 1,2 and 3 days after the operation. Method of measurement: patient tests.;Duration of postoperative mechanical ventilation. Timepoint: After detachment from the ventilator. Method of measurement: patients record.;Duration of hospitalization in the ICU. Timepoint: Upon completion of hospitalization in the ICU. Method of measurement: patients record.;Duration of hospitalization. Timepoint: at discharge. Method of measurement: patients record.

Secondary

MeasureTime frame
Cardiac Complications (ECG Changes and hemodynamic Status). Timepoint: On admission to 72 hours after surgery. Method of measurement: EKG.;Blood indicators: electrolyte changes, blood, allergic , liver and renal complications. Timepoint: Patient tests. Method of measurement: On admission to 72 hours after surgery.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlimohammad sadeghi meibodi

Rasht University of Medical Sciences

alimohammad_sadeghi@gums.ac.ir+98 13 3336 8633

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026